000 04176nam a22004695i 4500
999 _c120565
_d120565
_x1
001 120565
003 ES-MaUEC
005 20230102114048.0
006 a||||fo|||| 00| 0
007 cr nn nnnaamaa
008 200519s2020 gw a o |||| 0|eng d
020 _a9783030336790
024 7 _a10.1007/978-3-030-33679-0
_2doi
040 _aES-MaUEC
_bspa
_cES-MaUEC
_dES-MaUEC
050 4 _aRM301.25
_b2020 EB
245 1 0 _aSubstance Use Disorders :
_bFrom Etiology to Treatment
_cedited by Michael A. Nader, Yasmin L. Hurd
250 _aFirst edition
264 1 _aCham, Switzerland
_bSpringer International Publishing
_c2020
300 _a1 recurso en línea (X, 502 páginas)
_b1 ilustraciones
336 _2rdacontent
_aTexto
_btxt
337 _2rdamedia
_aelectrónico
_bc
338 _2rdacarrier
_arecurso electrónico
_bcr
347 _aArchivo de texto
_bPDF
490 0 _aHandbook of Experimental Pharmacology
_x0171-2004
_v258
490 0 _aBiomedical and Life Sciences (Springer-11642)
505 0 _a1. Methods for Population Research on Substance Use and Consequences -- 2. Translational Molecular Approaches in Substance Abuse Research -- 3. Small Molecule Neuropeptide-S and Melanocortin Receptor Ligands As Potential Treatments for Substance Use Disorders -- 4. Emerging Insights into Mu Opioid Pharmacology -- 5. Behavioral Pharmacology of Drugs Acting at Mu Opioid Receptors -- 6. The Rise and Fall of Kappa-Opioid Receptors in Drug Abuse Research -- 7. Clinical Trials for Opioid Use Disorder -- 8. Modelling Differential Vulnerability to Substance Use Disorder in Rodents: Neurobiological Mechanisms -- 9. Activity-Dependent Epigenetic Remodeling in Cocaine Use Disorder -- 10. Molecular Mechanisms of Amphetamines -- 11. Clinical Trials for Stimulant Use Disorders: Addressing Heterogeneities That May Undermine Treatment Outcomes -- 12. Molecular Mechanism and Cannabinoid Pharmacology -- 13. Pharmacotherapies for Cannabis Use Disorders: Clinical Challenges and Promising Therapeutic Agents -- 14. Molecular Mechanisms Associated with Nicotine Pharmacology and Dependence -- 15. Randomized Clinical Trials Investigating Innovative Interventions for Smoking Cessation in the Last Decade -- 16. Adolescent Vulnerability to Alcohol Use Disorder: Neurophysiological Mechanisms from Preclinical Studies -- 17. Medication Development for Alcohol Use Disorder: A Focus on Clinical Studies -- 18. Newly Emerging Drugs of Abuse.
520 3 _aThe purpose of this book is to provide a broad scope of substance use disorder research and how these findings can impact treatment outcomes. The research and outcomes described in this book represent important principles related to identifying and understanding factors related to substance use disorders. The first section is dedicated to methodology including population-based surveys, basic neuroanatomy, chemistry, molecular biology, behavioral models and brain imaging. The second section utilizes this methodology in research related to opioids, cocaine, marijuana, alcohol and nicotine. The book is aimed at both professionals (academics, clinicians, practitioners) and students or trainees.
988 _aSpringer_Biomedlife_23062020
650 7 _aFarmacología
_xInvestigación
_2embne
_9183058
650 7 _aIndustria farmacéutica
_xInvestigación
_2embne
_9138366
650 7 _aEtiología médica
_2embne
_9140556
700 1 _aNader, Michael A
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aHurd, Yasmin L
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
710 2 _aSpringerLink (Online service)
_0http://id.loc.gov/authorities/names/no2005046756
_1http://viaf.org/viaf/148105729
776 0 8 _iPrinted edition:
_z9783030336783
776 0 8 _iPrinted edition:
_z9783030336806
776 0 8 _iPrinted edition:
_z9783030336813
830 0 _aHandbook of Experimental Pharmacology,
_x0171-2004 ;
_v258
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-33679-0
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942 _2lcc
_cLE
998 _b07/2020
_dz
_eo
_zSI